Tech Company Financing Transactions

Inozyme Pharma Funding Round

Longitude Capital Management, New Enterprise Associates and Novo Ventures participated in a $49 million Series A capital raise for Inozyme Pharma. The round closed on 11/16/2017.

Transaction Overview

Company Name
Inozyme Pharma
Announced On
11/16/2017
Transaction Type
Venture Equity
Amount
$49,000,000
Round
Series A
Investors

Longitude Capital Management (Lead Investor) (Reinaldo Diaz)

New Enterprise Associates (Ed Mathers)

Novo Ventures (Martin Edwards)

Sanofi-Genzyme BioVentures

Proceeds Purpose
The company will use the proceeds from this financing to advance its lead enzyme replacement therapy for the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) into the clinic.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
280 Summer St. 5th Floor
Boston, MA 02210
USA
Phone
(857) 330-4340
Website
www.inozyme.com
Email Address
[email protected]
Overview
Inozyme Pharma (Nasdaq: INZY) is a biotechnology company developing new medicines to treat rare disorders of calcification. These diseases are characterized by mineral imbalances, which lead to over calcification of soft tissues and under mineralization of bone.
Profile
Inozyme Pharma LinkedIn Company Profile
Social Media
Inozyme Pharma Company Twitter Account
Company News
Inozyme Pharma News
Facebook
Inozyme Pharma on Facebook
YouTube
Inozyme Pharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Axel Bolte
  Axel Bolte LinkedIn Profile  Axel Bolte Twitter Account  Axel Bolte News  Axel Bolte on Facebook
Chief Operating Officer
Henric Bjarke
  Henric Bjarke LinkedIn Profile  Henric Bjarke Twitter Account  Henric Bjarke News  Henric Bjarke on Facebook
Chief Scientific Officer
David Thompson
  David Thompson LinkedIn Profile  David Thompson Twitter Account  David Thompson News  David Thompson on Facebook
Chief Technical Officer
Steven Jungles
  Steven Jungles LinkedIn Profile  Steven Jungles Twitter Account  Steven Jungles News  Steven Jungles on Facebook
VP - Finance
Stephen Basso
  Stephen Basso LinkedIn Profile  Stephen Basso Twitter Account  Stephen Basso News  Stephen Basso on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/16/2017: Monopar Therapeutics venture capital transaction
Next: 11/16/2017: ReFirm Labs venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.